ObesityNCT04073394
Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes
A study testing Standard Lifestyle Intervention and Modified Lifestyle Intervention in people with Obesity, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this protocol is to define an "individualized diet" approach based on obesity related phenotypes (pathophysiology obesity classification), which would increase weight loss, adherence, and weight loss maintenance. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity
- What is being tested?
- Standard Lifestyle Intervention and Modified Lifestyle Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 215 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jul 2020to 31 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults with obesity (BMI >30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and uncontrolled life-threatening comorbidities (i.e. unstable angina).
- Age: 18-65 years.
- Gender: Men or women.
Who cannot join
- Weight change greater than 3% in the previous 3 months (weight stable).
- History of bariatric surgery including lap band and bariatric endoscopy.
- Significant untreated psychiatric dysfunction including binge eating disorders and bulimia.
- Current use of anti-obesity pharmacotherapy, medications known to affect weight (e.g., corticosteroids) or GLP-1 agonist/analog for T2DM
- A positive score on the AUDIT-C questionnaire as judged by an investigator.
- Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
Trial locations and contacts
1 site in 1 country.
About this study
Official title: "Mayo Clinic Diet" Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes (PHENO-Diet Trial)
The purpose of this protocol is to define an "individualized diet" approach based on obesity related phenotypes (pathophysiology obesity classification), which would increase weight loss, adherence, and weight loss maintenance.
- Conditions
- Obesity
- Being tested
- Standard Lifestyle Intervention, Modified Lifestyle Intervention
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Lifestyle InterventionBehavioural
Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
Modified Lifestyle InterventionBehavioural
Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
| Study group | Role | What they receive |
|---|---|---|
| Standard Lifestyle Intervention | Active comparator | Participants in this group will be instructed to follow a standard low calorie diet, recommended to have 30 minutes of physical activity 3-5 days per week, and will be followed by a wellness couch weekly. Receives: Behavioral: Standard Lifestyle Intervention |
| Modified Lifestyle Intervention | Experimental | Participants in this group will have a tailored diet, exercise, and behavioral plan according to their obesity phenotype. Receives: Behavioral: Modified Lifestyle Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
12-week total body weight loss
Change in body weight during the 12 week study
Measured: 12 weeks
Secondary outcomes (11)
Responder Rate
Proportion of patients losing > 3% of total body weight
Measured: 12 weeks
Waist Circumference
Change in waist circumference (cm)
Measured: 12 weeks
Fat Loss
Change in fat mass during the 12 week study using DEXA
Measured: 12 weeks
Calorie Intake
Change in daily calorie intake
Measured: 12 weeks
Calories to Fullness
Change in calories consumed to fullness during the 12 week study using satiation test
Measured: 12 weeks
Gastric Emptying
Change in half gastric emptying time during the 12 week study using scintigraphy
Measured: 12 weeks
Gastric Emptying 2 Hours
Change in gastric emptying percentage at 2 hours during the 12 week study using scintigraphy
Measured: 12 weeks
Anxiety Level
Change is anxiety level during the 12 week study using the HADS-A scale
Measured: 12 weeks
Emotional Eating
Change is emotional eating level during the 12 week study using the TFEQ score
Measured: 12 weeks
Resting Metabolic Rate
Change in resting energy expenditure during the 12 week study using an indirect calorimetry
Measured: 12 weeks
Adherence
Adherence and compliance with program defined by the number of contacts with the team
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Aug 2019
- Study start6 Jul 2020
- Primary completion31 Jan 2022
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 215 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Andres J. Acosta, M.D., Ph.D., Mayo Clinic
- Investigators
- Andres Acosta, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04073394
- Sponsor's protocol ID
- 19-007485
- Status last verified
- Feb 2023
- First submitted
- 28 Aug 2019
- Last updated
- 3 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Anazco D, Koball A, Cifuentes L, Villamarin J, Friend J, Fansa S, Espinosa MA, Rieck TM, Grothe K, Camilleri M, Hurtado MD, Acosta A, Clark MM, Hensrud DD. Phenotype tailored lifestyle intervention for weight management in individuals with emotional eating: A secondary analysis of the PHENO-Diet trial. Obes Pillars. 2026 Jun 17;19:100284. doi: 10.1016/j.obpill.2026.100284. eCollection 2026 Sep.
PubMed 42382664Cifuentes L, Ghusn W, Feris F, Campos A, Sacoto D, De la Rosa A, McRae A, Rieck T, Mansfield S, Ewoldt J, Friend J, Grothe K, Lennon RJ, Hurtado MD, Clark MM, Camilleri M, Hensrud DD, Acosta A. Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study. EClinicalMedicine. 2023 Mar 24;58:101923. doi: 10.1016/j.eclinm.2023.101923. eCollection 2023 Apr.
PubMed 37007741
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Mayo Clinic Diet" Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes (PHENO-Diet Trial)
- ClinicalTrials.gov ID
- NCT04073394
- Acronym / sponsor ID
- 19-007485
- Conditions
- Obesity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 215 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 6 Jul 2020 (actual)
- Primary completion
- 31 Jan 2022 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 29 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this protocol is to define an "individualized diet" approach based on obesity related phenotypes (pathophysiology obesity classification), which would increase weight loss, adherence, and weight loss maintenance.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard Lifestyle Intervention | Active comparator | Behavioral: Standard Lifestyle InterventionParticipants in this group will be instructed to follow a standard low calorie diet, recommended to have 30 minutes of physical activity 3-5 days per week, and will be followed by a wellness couch weekly. |
| Modified Lifestyle Intervention | Experimental | Behavioral: Modified Lifestyle InterventionParticipants in this group will have a tailored diet, exercise, and behavioral plan according to their obesity phenotype. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults with obesity (BMI >30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and uncontrolled life-threatening comorbidities (i.e. unstable angina).
- Age: 18-65 years.
- Gender: Men or women.
Key exclusion criteria (6 listed)
- Weight change greater than 3% in the previous 3 months (weight stable).
- History of bariatric surgery including lap band and bariatric endoscopy.
- Significant untreated psychiatric dysfunction including binge eating disorders and bulimia.
- Current use of anti-obesity pharmacotherapy, medications known to affect weight (e.g., corticosteroids) or GLP-1 agonist/analog for T2DM
- A positive score on the AUDIT-C questionnaire as judged by an investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Lifestyle InterventionResearch team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program. | Behavioural | Standard Lifestyle Intervention |
| Modified Lifestyle InterventionResearch team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype. | Behavioural | Modified Lifestyle Intervention |
Primary outcome
12-week total body weight loss
Time frame: 12 weeks
Change in body weight during the 12 week study
11 secondary outcomes
Responder Rate
Time frame: 12 weeks
Waist Circumference
Time frame: 12 weeks
Fat Loss
Time frame: 12 weeks
Calorie Intake
Time frame: 12 weeks
Calories to Fullness
Time frame: 12 weeks
Gastric Emptying
Time frame: 12 weeks
Gastric Emptying 2 Hours
Time frame: 12 weeks
Anxiety Level
Time frame: 12 weeks
Emotional Eating
Time frame: 12 weeks
Resting Metabolic Rate
Time frame: 12 weeks
Adherence
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2023.
- Derived from this study: PubMed 42382664Anazco D, Koball A, Cifuentes L, Villamarin J, Friend J, Fansa S, Espinosa MA, Rieck TM, Grothe K, Camilleri M, Hurtado MD, Acosta A, Clark MM, Hensrud DD. Phenotype tailored lifestyle intervention for weight management in individuals with emotional eating: A secondary analysis of the PHENO-Diet trial. Obes Pillars. 2026 Jun 17;19:100284. doi: 10.1016/j.obpill.2026.100284. eCollection 2026 Sep.
- Derived from this study: PubMed 37007741Cifuentes L, Ghusn W, Feris F, Campos A, Sacoto D, De la Rosa A, McRae A, Rieck T, Mansfield S, Ewoldt J, Friend J, Grothe K, Lennon RJ, Hurtado MD, Clark MM, Camilleri M, Hensrud DD, Acosta A. Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study. EClinicalMedicine. 2023 Mar 24;58:101923. doi: 10.1016/j.eclinm.2023.101923. eCollection 2023 Apr.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andres Acosta, MD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Lifestyle Intervention and Modified Lifestyle Intervention in people with Obesity, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
12-week total body weight loss (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04073394, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2023.